reports
Incannex Reactivates Share Repurchase Program, Underscoring Confidence...
Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position Board initiates buyback activity following period of inactivity, with repurchases executed over the past two trading days MELBOURNE, Australia and NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has reactivated its previously approved share repurchase program, with the program having been active over the past two trading days. The Co...
Incannex Healthcare Announces Partnership with the AASM Foundation in ...
Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research Company Joins AASM Foundation Corporate Recognition Program and Sponsors Junior Investigator Research Grant as IHL-42X Advances Toward Potential Oral Treatment for Obstructive Sleep Apnea MELBOURNE, Australia and NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced it has entered into a Partnership Agreement with the American Academy ...
Incannex Highlights Strong Balance Sheet with Approximately $75 Millio...
Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development Company well-funded to complete DReAMzz Phase 2 study while preserving capital for optimized Phase 3 program MELBOURNE, Australia and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today reported that it holds approximately $75 million in cash with no debt, following the completion of its recently announced financin...
Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement
Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement MELBOURNE, Australia and NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced that it has regained compliance with the Nasdaq minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company received written confirmation from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement after its common stock maintai...
Incannex Healthcare Inc. Announces Pricing of $10 Million Registered D...
Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules NEW YORK and MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IHXL), ("Incannex" or the “Company") a clinical-stage biopharmaceutical company leading the way in developing combination medicines, today announced that it has entered into a securities purchase agreement with healthcare-dedicated institutional investors for the issuance and sale of 2,000,000 shares of its common stock (or common stock equivalents in lieu thereof...
Incannex Strengthens Clinical Development Pathway for IHL-42X Followin...
Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 program MELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced an enhanced clinical development strategy for IHL-42X, its lead oral drug candidate for the treatment of obstructive sleep apnea (OSA), following statistically si...
Incannex Announces Reverse Stock Split
Incannex Announces Reverse Stock Split Incannex’s common stock is expected to begin trading on a post-split adjusted basis on February 27, 2026 MELBOURNE, Australia and NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, today announced that the board of directors of the Company approved a 1-for-30 reverse stock split (the “Reverse Split”) of the Company’s common stock. The Reverse Split was approved by the...
Incannex Healthcare Announces Additional Appointments to Clinical Advi...
Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board Expands clinical expertise to support disciplined advancement of the PSX-001 program MELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board (“CAB”): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide independent...
Incannex Healthcare Announces Formation of Clinical Advisory Board for...
Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program Strengthens clinical and regulatory guidance as PSX-001 advances to its next phase of development MELBOURNE, Australia and NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces the formation of a Clinical Advisory Board (CAB) to support the continued advancement of its PSX-001 development program in generalized anxiety disorder. The newly established CAB has been formed to ...
Incannex Healthcare Wins Research and Development Award for Obstructiv...
Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards MELBOURNE, Australia and NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has been honored with the Research and Development Award in the Respiratory Disorders category of the 2025 Clinical Trials Arena Excellence Awards for its work advancing IHL-42X, the Company’s oral fixed-dose combination product ...
Incannex Healthcare Delivers Transformational 2025 Progress and Outlin...
Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026 Company enters 2026 with over $70 million in cash, two positive Phase 2 programs, FDA Fast Track Designation and runway well into 2027 MELBOURNE, Australia and NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, provides a 2025 corporate year-in-review and outlook for 2026, highlighting substantial clinical, regulatory and financial progress that positions the Company...
Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive...
Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA) MELBOURNE, Australia and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IHL-42X, the Company’s oral fixed-dose combination product candidate for the treatment of obstructive sleep apnea (OSA). The Fast Track designation was supported by promising safety, efficacy, and pharmacokine...
Incannex Provides Shareholder Update Highlighting Clinical Progress, C...
Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus Company outlines continued progress across clinical, regulatory, and capital initiatives positioning for sustained long-term growth MELBOURNE, Australia and NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL)(“Incannex” or the “Company”), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, provides a shareholder update highlighting recent progress across its clinical and c...
Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with...
Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement MELBOURNE, Australia and NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). Incannex now has until April 20, 2026...
Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-0...
Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder Psi-GAD delivers statistically significant and clinically meaningful improvements across validated measures of anxiety, mood, disability, and quality of life; results establish PSX-001 as a leading psilocybin-assisted therapy in development globally MELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) is pleased to report positive data from its Phase 2 clinical trial of PSX-001 (formerly ...
Incannex Healthcare Authorizes $20 Million Share Repurchase Program
Incannex Healthcare Authorizes $20 Million Share Repurchase Program MELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact conditions, today announced that its Board of Directors has authorized a share repurchase program (the “Repurchase Program”) for up to $20 million of the Company’s outstanding shares of common stock (“Common Stock”). Under the Repurchase Program, the Company may repurchase shares of...
Incannex Receives Positive Patient-Reported Outcomes and Compelling Ph...
Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea Exit interviews and clinical results reinforce strong potential for meaningful improvements in sleep quality, cognitive function, and daily life MELBOURNE, Australia and NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for prevalent medical conditions, today announced new patient-reported outcome findings from a subset of participants in its...
Incannex Confirms Strong Cash Position; No Plans or Requirement to Ful...
Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term MELBOURNE, Australia, July 31, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) announced, in response to recent questions it received from a number of its stockholders, that it does not presently intend to use the full capacity available under its at the market offering program (the “ATM”) in the near-term. As previously disclosed in the Company’s Form 8-K filed with the U.S. Securities and Exchange Commission on July 24, 2025, the Company is und...
Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of...
Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X Statistically and clinically significant improvements across key clinical endpoints; IHL-42X reduced AHI by up to 83% from baseline. IHL-42X demonstrates compelling clinical benefit and an outstanding safety profile that exceeded expectations. NEW YORK and MELBOURNE, Australia, July 30, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) is excited to share positive topline results from its RePOSA Phase 2 clinical trial evaluating IHL-42X, a novel oral drug candidate ...
Incannex Healthcare Expands Clinical Advisory Board to Support Obstruc...
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo NEW YORK and MELBOURNE, Australia, July 25, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the appointment of Charlene E. Gamaldo, M.D. to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board. Incannex Chief Medical Officer Dr. Lou Barbato commented:“We are fortunate to wel...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.